Objective: To evaluate the effectiveness and conduct a comparative analysis of consumer qualities of desmopressin intranasal drops 0.01% 5ml ("Biopharm", Georgia) in patients with central diabetes insipidus (CDI). Materials and Methods: The study included 9 patients (3 men and 6 women, mean age 44 ± 12 years) diagnosed with CDI. Patients for 7 days were switched to desmopressin intranasal drops 0.01% (JSC "Biopharm" Georgia) from there basal desmopressin preparations by means of recalculating daily dose by proposed formular: 10 mg (2 drops) of desmopressin intranasal drops = 0.2 mg of desmopressin tableted = 10 micrograms (one dose) of intranasal spray metered desmopressin = 120 mcg sublingual tablets of desmopressin. Safety biochemical parameters, efficiency to control of the main manifestations of CDI, increase in urine specific gravity, quality of life, basic consumer properties of different desmopressin preparation were evaluates at baseline and after treatment period. Results: Desmopressin nasal drops 0.01% showed to be an effective drug for the treatment of patients with CDI. Dose calculation algorithm daily was adequate in most patients. Hyponatremia was detected in 2 out of 9 patients during the study period but has been related to study drug alone in one case. The investigational drug was marked convenient to use by less than 25% of patients which may be associated with the pharmacological form of the drug as intranasal drops with special storage conditions (refrigerator). Conclusions: The drug desmopressin intranasal drops can be recommended as a second line (reserve) therapy in the treatment of patients CDI. Sodium levels should be checked during initiation of therapy.

ACTH-ectopic hypercortisolism is one of the most соmplex variants of endocrine pathology presenting with v arious metabolic changes. Its early localization still represents a cornerstone of radical treatment of such patients. In this article w e discuss a clinical case of woman with ectopic secretion of ACTH by malignant lung carcinoid, which localization and therefore surgical treatment wаs possible only after three-year period of extensive diagnostic workup.

АКТГ-эктопированный гиперкортицизм является одним из наиболее тяжелых вариантов эндокринной патологии и проявляется множественными нарушениями обмена веществ. Его ранняя топическая диагностика остается до сих пор краеугольным камнем радикального лечения пациентов. Мы представляем клинический случай с эктопической секрецией АКТГ злокачественным карциноидом легкого, выявление которого и, следовательно, оперативное лечение, стало возможным только после трехлетнего периода интенсивных поисков источника заболевания